Validation of Radio-induced Damage Biomarkers (BIOM-DRI)
Bone Metastasis, Malignant Hemopathy
About this trial
This is an interventional prevention trial for Bone Metastasis focused on measuring Bio-markers, Radiation, Appropriate therapeutic strategy, Total Body Irradiation, Partial Body Irradiation
Eligibility Criteria
Inclusion Criteria:
- More than 18 years old
- For the group A:
Patient suffering from a malignant blood disease requiring a whole-body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, during 3 days.
- OR For the group B:
Patient with one (or more) pelvis metastasis requiring radiation therapy without concomitant chemotherapy, according to the following protocol: 4 Gray per day for 5 days.
Exclusion Criteria:
- More than 70 years old,
- Subject presenting abnormal blood count (grade 3),
- Person with a not controlled chronic illness,
- Subject presenting an abnormal hepatic assessment (grade 3),
- Subject having already received ionizing treatments,
- Subject reached HIV, hepatitis C or any other progressive infectious diseases,
- Pregnant women or nursing mothers,
- Person under protection of justice or unable to give consent.
Sites / Locations
- Institut de Cancérologie Lucien Neuwirth
- Institut Gustave Roussy
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Total Body Irradiation
Partial Body Irradiation
Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.